Radiofrequency Ablation of Colorectal Liver Metastases Downstaged by Chemotherapy. Acta radiologica (Stockholm, Sweden : 1987) [Acta Radiol] Journal article | | Title | Radiofrequency Ablation of Colorectal Liver Metastases Downstaged by Chemotherapy. | | Author(s) | Knudsen AR, Kannerup AS, Mortensen FV, Nielsen DT | | Institution | Department of Surgical Gastroenterology L. | | Source | Acta Radiol 2009 Jun 1.:1-6. | | Abstract | Background: Radiofrequency ablation (RFA) continues to evolve, improving the potentials of this technique. It is now a widely used procedure in the treatment of patients with unresectable colorectal liver metastases, increasing the number of potentially curable patients.
Purpose: To evaluate the long-term survival of patients treated by RFA for colorectal liver metastases after downstaging by systemic chemotherapy. Material and
Methods: In a retrospective review of our prospective colorectal liver metastasis RFA database, 36 patients (20 males, 16 females; median age 67 years) were identified during an 8-year period (1999-2007). All patients were initially unsuitable for local treatment, and referred to systemic chemotherapy by our multidisciplinary team. Multinodularity and/or location of tumor was the main cause of patients being unsuitable for local treatment. Chemotherapy mainly consisted of 5-fluorouracil and leucovorin combined with oxaliplatin or irinotecan. After downstaging with chemotherapy, patients were treated by RFA. Patients with extrahepatic disease were excluded from RFA treatment. Pre- and posttreatment evaluation was performed with multidetector computed tomography (MDCT) scans.
Results: The median time from diagnosis of hepatic metastases to first RFA was 10 months. A total of 158 tumors were treated with RFA during the study period. Median follow-up period was 27 months. The estimated median survival time after diagnosis of hepatic metastasis was 39 months, with a 5-year survival rate of 34%.
Conclusion: In selected patients with colorectal liver metastases downstaged by chemotherapy, RFA is an important modality that may contribute to improved survival. Furthermore, all patients responding to systemic chemotherapy should be re-evaluated by a multidisciplinary team. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19488894 |
|
|
| |
Advertise on this site.
| | |
|
